<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>                  17     PATIENT COUNSELING INFORMATION<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.1     Administration<BR>                     <BR>                        Inform patients that Zortress should be taken orally twice a day approximately 12 hours apart consistently either with or without food.<BR>                        Inform patients to avoid grapefruit and grapefruit juice which increase blood drug concentrations of Zortress. [See <BR>                           Warnings and Precautions (5.19)]<BR>                        Advise patients that Zortress should be used concurrently with reduced doses of cyclosporine and that any change in doses of these medications should be made under physician supervision. A change in the cyclosporine dose may also require a change in the dosage of Zortress. <BR>                        Inform patients of the necessity of repeated laboratory tests according to physician recommendations while they are taking Zortress.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.2     Development of Lymphomas and Other Malignancies<BR>                     <BR>                        Inform patients they are at risk of developing lymphomas and other malignancies, particularly of the skin, due to immunosuppression. Advise patients to limit exposure to sunlight and ultraviolet (UV) light by wearing protective clothing and using a sunscreen with a high protection factor. [See <BR>                           Warnings and Precautions (5.2)] <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.3     Increased Risk of Infection<BR>                     <BR>                        Inform patients they are at increased risk of developing a variety of infections, including opportunistic infections, due to immunosuppression. Advise patients to contact their physician if they develop any symptoms of infection. [See <BR>                           Warnings and Precautions (5.3, 5.13)] <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.4     Kidney Graft Thrombosis<BR>                     <BR>                        Inform patients that Zortress has been associated with an increased risk of kidney arterial and venous thrombosis, resulting in graft loss, usually within the first 30 days post-transplantation. [See Warnings and Precautions (5.4)]<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.5     Zortress and Calcineurin Inhibitor-Induced Nephrotoxicity<BR>                     <BR>                        Advise patients of the risks of impaired kidney function with the combination of Zortress and cyclosporine as well as the need for routine blood concentration monitoring for both drugs. Advise patients of the importance of serum creatinine  monitoring. [See  Warnings and Precautions (5.6)]<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.6     Angioedema<BR>                     <BR>                        Inform patients of the risk of angioedema and that concomitant use of angiotensin converting enzyme (ACE) inhibitors may increase this risk. Advise patients to seek prompt medical attention if symptoms occur. [See Warnings and<BR>                            <BR>                           Precautions (5.8)]<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.7     Wound Healing Complications and Fluid Accumulation <BR>                     <BR>                        Inform patients the use of Zortress has been associated with impaired or delayed wound healing, fluid accumulation and the need for careful observation of their incision site. [See <BR>                           Warnings and Precautions (5.9)] <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.8     Interstitial lung disease/Non-Infectious Pneumonitis<BR>                     <BR>                        Inform patients the use of Zortress may increase the risk of non-infectious pneumonitis. Advise patients to seek medical attention if they develop clinical symptoms consistent with pneumonia. [See Warnings and Precautions (5.10)]<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.9     Hyperlipidemia<BR>                     <BR>                        Inform patients the use of Zortress has been associated with increased serum cholesterol and triglycerides that may require treatment and the need for monitoring of blood lipid concentrations. [See <BR>                           Warnings and Precautions<BR>                            <BR>                           (5.11)]<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.10     Proteinuria<BR>                     <BR>                        Inform patients the use of Zortress has been associated with an increased risk of proteinuria. [See Warnings and Precautions (5.12)]<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.11     Pregnancy<BR>                     <BR>                        Advise women of childbearing age to avoid becoming pregnant throughout treatment and for 8 weeks after Zortress therapy has stopped. <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.12     Medications that Interfere with Zortress<BR>                     <BR>                        Some medications can increase or decrease blood concentrations of Zortress. Advise patients to inform their physician if they are taking any of the following: antifungals, antibiotics, antivirals, anti-epileptic medicines including carbamazepine, phenytoin and barbiturates, herbal/dietary supplements (St. John’s Wort), and/or rifampin. [See Warnings and Precautions (5.14)]<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.13     New Onset Diabetes<BR>                     <BR>                        Inform patients the use of Zortress may increase the risk of diabetes mellitus and to contact their physician if they develop symptoms. [See Warnings and Precautions (5.16)]<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.14     Immunizations<BR>                     <BR>                        Inform patients that vaccinations may be less effective while they are being treated with Zortress. Advise patients live vaccines should be avoided. [See Warnings and Precautions (5.18)]<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.15     Patient with Hereditary Disorders<BR>                     <BR>                        Advise patients to inform their physicians that if they have hereditary disorders of galactose intolerance (Lapp-lactase deficiency or glucose-galactose malabsorption) not to take Zortress. [See Warnings and Precautions (5.20)]<BR>                        Manufactured by:<BR>Novartis Pharma Stein AG<BR>Stein, Switzerland<BR>                        Distributed by:<BR>Novartis Pharmaceuticals Corporation <BR>East Hanover, New Jersey 07936<BR>                        © Novartis<BR>                        T2013-09<BR>February 2013<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>